An RGD fragment, a method for preparing a polypeptide using the same, and its application
By using Fmoc-Arg(Pbf)-Gly-Asp(OtBu)-OH modified RGD fragments to couple amino acids in solid phase synthesis method, the problem of cumbersome steps and low efficiency in the synthesis of RGD peptides is solved, and high efficiency is achieved. The synthesis of low-impact peptides significantly improves the purity and yield of the peptide.
Patent Information
- Application Number
- CN202311430717.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2022-10-31
- Filing Date
- 2023-10-31
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2043-10-31
AI Technical Summary
In the prior art, the synthesis process of RGD peptides is cumbersome, low efficiency, long time consuming and easy to introduce missing impurities and insertion impurities.
Fmoc-Arg(Pbf)-Gly-Asp(OtBu)-OH is used as the modified RGD fragment, and the amino acid residues modified by side chain protection groups are successively coupled in the condensation system through solid phase synthesis method, and finally the RGD fragment is coupled. , the side chain protection group was removed through cleavage and RGD peptide was obtained.
The coupling reaction steps for peptide synthesis are shortened, the synthesis efficiency is improved, the side reactions are reduced, the generation of missing impurities and insertion impurities is avoided, and the purity and yield of the peptide are significantly improved.
Smart Images

Figure BDA0004523556980000051 
Figure BDA0004523556980000061 
Figure BDA0004523556980000062
Abstract
Description
Technical Field
[0001] The invention belongs to the field of chemical synthesis, and specifically relates to an RGD fragment, a method for preparing a polypeptide using the same, and application thereof. Background Art
[0002] RGD peptide is a short peptide containing Arg-Gly-Asp sequence, which is widely present in organisms and is the recognition site for the interaction between integrin and its ligand protein (Pierschbacher, MD, Ruoslahti, E., 1984. Cell attachment activity of fibronectin can be beduplicated by small synthetic fragments of the molecule. Nature 309, 30-33). Since the RGD sequence contained in fibrinogen was first reported as a cell recognition site in 1984, RGD peptide and its derivatives have become a hot topic of concern and research for many scholars. The most common matrix proteins containing RGD sequences in the human body include fibronectin, laminin, vitronectin, collagen, thrombin, etc. (Temming K, Schiffelers RM, Molema G, et al. Kok RJ. RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumor vasculature [J]. Drug Resist Updat, 2005, 8 (6): 381-402).
[0003] RGD sequences are widely distributed in extracellular matrix proteins. Extracellular matrix proteins recognize and bind to integrin receptors on the cell membrane through RGD sequences, mediate the interaction between cells and extracellular matrix, and between cells, and participate in pathological processes such as angiogenesis, tumor occurrence, development, infiltration and metastasis.
[0004] At present, when there is an RGD peptide sequence in the peptide chain, the main method used is to couple amino acids one by one. This method is cumbersome, inefficient, time-consuming, and prone to introducing missing impurities and inserted impurities. Summary of the invention
[0005] In order to overcome the defects of the above-mentioned steps being complicated, inefficient, time-consuming and containing many impurities, the present invention provides an RGD fragment, a method for preparing a polypeptide using the same and its application; specifically, the present invention adopts Fmoc-Arg(Pbf)-Gly-Asp(OtBu)-OH amino acid solid phase synthesis of a polypeptide containing an RGD fragment.
[0006] In order to solve the defects of the prior art, the first aspect of the present invention provides a modified RGD fragment, which includes Arg-Gly-Asp, and Pbf is modified on the side chain of Arg, OtBu is modified on the side chain of Asp, and Arg also has an amine protecting group such as Fmoc (2-chlorobenzyloxycarbonyl).
[0007] In certain embodiments, the RGD fragment is Fmoc-Arg(Pbf)-Gly-Asp(OtBu)-OH.
[0008] The second aspect of the present invention provides a method for synthesizing an RGD peptide, the method comprising using a solid phase material as a carrier, sequentially coupling amino acid residues modified with side chain protecting groups in a condensation system, and finally coupling the RGD fragment as described in the first aspect of the present invention, and removing the side chain protecting groups by cleavage to obtain the RGD peptide. Preferably, the RGD peptide is a 30 peptide, and its amino acid sequence is shown in SEQ ID NO: 1. More preferably, the RGD fragment is coupled twice in succession.
[0009] The third aspect of the present invention provides a method for synthesizing an RGD peptide, the method comprising using a solid phase material as a carrier, first coupling Fmoc-Gly-Gly-OH to the solid phase material in a condensation system, then sequentially coupling amino acid residues modified with side chain protecting groups, and removing the side chain protecting groups by cleavage to obtain the RGD peptide. Preferably, the RGD peptide is a 30 peptide, and its amino acid sequence is shown in SEQ ID NO: 1.
[0010] In certain embodiments, Fmoc-Gly-Gly-OH is first connected to the solid phase material, and then the amino acid residues modified with side chain protecting groups are coupled in sequence. Then, the RGD fragment as described in the first aspect of the present invention is coupled twice, and the side chain protecting groups are removed by cleavage to obtain the RGD peptide.
[0011] In certain embodiments, the coupling reaction is performed from the C-terminus to the N-terminus, and / or the solid phase material is a resin; for example, the solid phase material is Rink amide AM Resin resin or Rink amide MHBA Resin resin. The resin may be a solid phase support resin in which the C-terminus of the polypeptide obtained after cleavage ends with an amide.
[0012] In certain embodiments, the amino acid modified with the side chain protecting group is Fmoc-X-OH, wherein X is an amino acid residue, and preferably the side chain of the amino acid residue is further modified with one or more of the following protecting groups: tBu, Trt, OtBu and Pbf.
[0013] In certain embodiments, the Fmoc-X-OH is Fmoc-Met-OH, Fmoc-Ser(tBu)-OH, Fmoc-Leu-OH, Fmoc-Pro-OH, Fmoc-Asn(Trt)-OH, Fmoc-Ala-OH, Fmoc-Val-OH, Fmoc-His(Trt)-OH, Fmoc-Gln(Trt)-OH, Fmoc-Phe-OH, Fmoc-Asp(OtBu)-OH or Fmoc-Arg(Pbf)-OH.
[0014] In certain embodiments, the condensation system is HOBT / DIC, which is first subjected to Fmoc protection before the coupling. Preferably,
[0015] The de-Fmoc protection uses a PIP / DMF solution;
[0016] The cleavage reagent used in the cleavage is a mixture of TFA / Mpr / H2O / DMS;
[0017] More preferably, the de-Fmoc protection uses a 20% PIP / DMF solution;
[0018] In the lysis reagent, the volume ratio of TFA / Mpr / H2O / DMS is 92:2:2:2;
[0019] After cleavage, the RGD peptide is obtained by filtration, concentration and precipitation, preferably by adding isopropyl ether for precipitation.
[0020] In certain embodiments, the condensation reagent used in the coupling reaction is one or more of 1-ethyl-(3-dimethylaminopropyl)carbodiimide (EDCI) / N-hydroxysuccinimide (HOSu), N,N-carbonyldiimidazole (CDI) / base buffer, 1,3-dicyclohexylcarbodiimide (DCC) / N-hydroxysuccinimide (HOSu), pivaloyl chloride (PivCl) and thionyl chloride (SOCl2) / dichloromethane (DCM), the coupling reaction temperature is 10-40°C, and / or the coupling reaction time is 1-3.5 hours.
[0021] In certain embodiments, the coupling reaction temperature is one of 15±2°C, 25±2°C and 35±2°C; the coupling reaction time is one of 1h, 2h and 3h.
[0022] In certain embodiments, the coupling reaction comprises coupling the following protected amino acids sequentially from C-terminus to N-terminus: Fmoc-Met-OH; Fmoc-Gly-Gly-OH or Fmoc-Gly-OH, Fmoc-Gly-OH; Fmoc-Ser(tBu)-OH, Fmoc-Leu-OH, Fmoc-Pro-OH, Fmoc-Ser(tBu)-OH, Fmoc-Asn(Trt)-OH, Fmoc-Leu-OH, Fmoc-Ala-OH, Fmoc-Val-OH, Fmoc-Leu-OH, Fmoc-His(Trt)-OH -OH, Fmoc-Leu-OH, Fmoc-Val-OH, Fmoc-Pro-OH, Fmoc-Gln(Trt)-OH, Fmoc-Phe-OH, Fmoc-Asp(OtBu)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-His(T rt)-OH, Fmoc-Ser(tBu)-OH, Fmoc-His(Trt)-OH, Fmoc-Met-OH, Fmoc-Arg(Pbf)-Gly-Asp(OtBu)-OH, Fmoc-Arg(Pbf)-Gly-Asp(OtBu)-OH.
[0023] The fourth aspect of the present invention provides a method for preparing the RGD fragment according to the first aspect of the present invention, the preparation method comprising:
[0024] (a) dissolving amino acids Fmoc-Arg(Pbf)-OH and H-Gly-OH and mixing with a condensation reagent, and stirring to obtain Fmoc-Arg(Pbf)-Gly;
[0025] (b) mixing Fmoc-Arg(Pbf)-Gly, H-Asp(OtBu)-OH and a condensation reagent, and stirring to obtain the RGD fragment;
[0026] In (a) and (b), the condensation reagent is one or more of EDCI / HOSu, CDI / base, DCC / HOSu, PivCl and SOCl2 / DCM;
[0027] Preferably, the condensation reagent is EDCI / HOSu.
[0028] The fifth aspect of the present invention provides use of the RGD fragment as described in the first aspect of the present invention in the preparation of polypeptide drugs.
[0029] On the basis of being in accordance with the common sense in the art, the above-mentioned preferred conditions can be arbitrarily combined to obtain the preferred embodiments of the present invention.
[0030] The reagents and raw materials used in the present invention are commercially available.
[0031] The positive and progressive effects of the present invention are:
[0032] 1. The method for synthesizing Fmoc-Arg(Pbf)-Gly-Asp(OtBu)-OH provided by the present invention shortens the coupling reaction steps during the solid phase synthesis of the RGD sequence of the polypeptide and improves the synthesis efficiency.
[0033] 2. The method for synthesizing 30 peptides from the Fmoc-Gly-Gly-OH amino acid fragment provided by the present invention only requires 29 coupling reactions, thereby improving synthesis efficiency, reducing side reactions, and avoiding the generation of corresponding missing impurities and inserted impurities.
[0034] 3. The method for synthesizing a 30-mer peptide containing an RGD fragment from an Fmoc-Arg(Pbf)-Gly-Asp(OtBu)-OH amino acid fragment provided by the present invention only requires 26 coupling reactions, thereby improving synthesis efficiency, reducing side reactions, and avoiding the generation of corresponding missing impurities and inserted impurities.
[0035] 4. The method provided by the present invention for synthesizing a 30-mer peptide containing an RGD fragment from Fmoc-Arg(Pbf)-Gly-Asp(OtBu)-OH and Fmoc-Gly-Gly-OH amino acid fragments only requires 25 coupling reactions, thereby improving synthesis efficiency, reducing side reactions, and avoiding the generation of corresponding missing impurities and inserted impurities. BRIEF DESCRIPTION OF THE DRAWINGS
[0036] Figure 1 This is the result of solid phase synthesis using Fmoc-Gly-Gly-OH.
[0037] Figure 2 This is the result of solid phase synthesis using Fmoc-Arg(Pbf)-Gly-Asp(OtBu)-OH.
[0038] Figure 3 The results are shown after amino acid coupling one by one.
[0039] Figure 4 This is the result of solid phase synthesis using Fmoc-Gly-Gly-OH and Fmoc-Arg(Pbf)-Gly-Asp(OtBu)-OH. DETAILED DESCRIPTION
[0040] The present invention is further described below by way of examples, but the present invention is not limited to the scope of the examples. The experimental methods in the following examples without specifying specific conditions are carried out according to conventional methods and conditions, or selected according to the product specifications.
[0041] 1. The specific route for synthesizing Fmoc-Arg(Pbf)-Gly-Asp(OtBu)-OH provided by the present invention is as follows:
[0042]
[0043] 2. The specific route for synthesizing 30 peptides using the Fmoc-Gly-Gly-OH amino acid fragment is as follows:
[0044]
[0045] 3. The specific route for synthesizing a 30-mer peptide containing an RGD fragment using the Fmoc-Arg(Pbf)-Gly-Asp(OtBu)-OH amino acid fragment is as follows:
[0046]
[0047] 4. The specific route for synthesizing a 30-mer peptide containing an RGD fragment using Fmoc-Arg(Pbf)-Gly-Asp(OtBu)-OH and Fmoc-Gly-Gly-OH amino acid fragments is as follows:
[0048]
[0049] The sequence of the RGD peptide (30 peptides) after removing all protecting groups is: RGDRGDMHSHRDFQPVLHLVALNSPLSGGM (SEQ ID NO: 1).
[0050] The present invention is further described below in conjunction with specific embodiments.
[0051] Description of abbreviations in this invention:
[0052] Fomc:9-Fluorenylmethoxycarbonyl
[0053] HOBt: 1-Hydroxybenzotriazole
[0054] DIC: N,N-diisopropylcarbodiimide
[0055] DMF: dimethylformamide
[0056] PIP: Piperidine
[0057] CDI: N,N-Carbonyldiimidazole
[0058] base: base buffer
[0059] DCC: 1,3-Dicyclohexylcarbodiimide
[0060] HOSu: N-hydroxysuccinimide
[0061] PivCl: trimethylacetyl chloride
[0062] SOCl2: Sulfonyl chloride
[0063] DCM: dichloromethane
[0064] TFA: trifluoroacetic acid
[0065] Mpr: mercaptopropionic acid
[0066] DMS: Dimethyl sulfide
[0067] CAS number of intermediate 1Fmoc-Arg(Pbf)-Gly: 660846-80-0
[0068] CAS number of H-Asp(OtBu)-OH: 154445-77-9
[0069] CAS number of Fmoc-Gly-Gly-OH: 35665-38-4
[0070] Example 1. Solid Phase Synthesis of RGD Peptide Using Fmoc-Gly-Gly-OH
[0071] 1.1 Preparation of Fmoc-Gly-Gly-OH
[0072] Fmoc-Gly-OH and H-Gly-OH were added to a reaction kettle, and an appropriate amount of 1-ethyl-(3-dimethylaminopropyl)carbodiimide (EDCI) / N-hydroxysuccinimide (HOSu) was added; the mixture was stirred for condensation reaction to obtain Fmoc-Gly-Gly-OH.
[0073] 1.2 Synthesis of peptide resin
[0074] The polypeptide resin is: Arg(Pbf)-Gly-Asp(OtBu)-Arg(Pbf)-Gly-Asp(OtBu)-Met-His(Trt)-Ser(tBu)-His(Trt)-Arg(Pbf)-Asp(OtBu)-Phe-Gln(Trt)-Pro-Val-Leu-His(Trt)-Leu-Val-Ala-Leu-Asn(Trt)-Ser(tBu)-Pro-Leu-Ser(tBu)-Gly-Gly-Met-Rink amideMHBA Resin resin.
[0075] Rink amide MHBA Resin resin was used as the starting carrier, and the peptide resin was prepared by coupling with the protected amino acids shown in Table 1 in sequence through Fmoc removal and coupling reaction. The protected amino acids corresponding to the protected amino acids used in this example are shown in Table 1 below, wherein the Fmoc-Gly-Gly-OH fragment was used to reduce the coupling reaction steps and improve the efficiency.
[0076] Table 1 Protected amino acids
[0077] Amino acid number Protect amino acids Molecular weight 30 Fmoc-Met-OH 371.45 29-28 Fmoc-Gly-Gly-OH 354.36 27 Fmoc-Ser(tBu)-OH 383.44 26 Fmoc-Leu-OH 353.41 25 Fmoc-Pro-OH 337.37 24 Fmoc-Ser(tBu)-OH 383.44 23 Fmoc-Asn(Trt)-OH 596.67 22 Fmoc-Leu-OH 353.41 21 Fmoc-Ala-OH 311.33 20 Fmoc-Val-OH 339.39 19 Fmoc-Leu-OH 353.41 18 Fmoc-His(Trt)-OH 619.71 17 Fmoc-Leu-OH 353.41 16 Fmoc-Val-OH 339.39 15 Fmoc-Pro-OH 337.37 14 Fmoc-Gln(Trt)-OH 610.70 13 Fmoc-Phe-OH 387.43 12 Fmoc-Asp(OtBu)-OH 411.45 11 Fmoc-Arg(Pbf)-OH 648.77 10 Fmoc-His(Trt)-OH 619.71 9 Fmoc-Ser(tBu)-OH 383.44 8 Fmoc-His(Trt)-OH 619.71 7 Fmoc-Met-OH 371.45 6 Fmoc-Asp(OtBu)-OH 411.45 5 Fmoc-Gly-Gly-OH 354.36 4 Fmoc-Arg(Pbf)-OH 648.77 3 Fmoc-Asp(OtBu)-OH 411.45 2 Fmoc-Gly-OH 354.36 1 Fmoc-Arg(Pbf)-OH 648.77
[0078] The preparation is carried out one by one from the C-terminus to the N-terminus according to the amino acid sequence (from large to small). Take Rink amide MHBA Resin resin (substitution value S = 0.37mmol / g). The condensation system adopts HOBT / DIC; the coupling reaction temperature is controlled at 25±5℃, and the coupling reaction time is 1.5-3.5h; 20% PIP / DMF solution is used for deprotection (removal of Fmoc protection), for example, (Pbf) and (OtBu) are the side chain protecting groups of amino acids. The deprotection time of S30-S16 is 5+10min; the deprotection time of S15-S1 is 5+15min; filter to obtain the resin without Fmoc, that is, the polypeptide resin, and set it aside.
[0079] 1.3 Preparation of crude peptide
[0080] The polypeptide resin prepared in Example 1.2 was added with a cleavage reagent having a volume ratio of TFA / Mpr / H2O / DMS=92 / 2 / 2 / 2, stirred evenly, and reacted at room temperature for 4 hours. The reaction mixture was filtered using a sand core funnel, and filtrate 1 was collected. The resin was then washed 3 times with a small amount of TFA (analytical grade reagent, AR) to collect filtrate 2, and filtrate 1 and filtrate 2 were combined. The combined filtrate was concentrated by rotary evaporation under reduced pressure, and the concentrated solution was added to isopropyl ether and allowed to stand. The sample precipitated and settled, and the solid precipitate was collected and dried to obtain a white powder, which was the crude polypeptide of the present invention, with a purity of 62.93%. Figure 1 shown.
[0081] Example 2. Solid phase synthesis of a 30-mer peptide containing the RGDRGD fragment using Fmoc-Arg(Pbf)-Gly-Asp(OtBu)-OH
[0082] 2.1 Preparation of the starting material of the present invention by liquid phase synthesis: Fmoc-Arg(Pbf)-Gly-Asp(OtBu)-OH
[0083] Dissolve the amino acids Fmoc-Arg(Pbf)-OH and H-Gly-OH, add them to a reaction kettle, add an appropriate amount of 1-ethyl-(3-dimethylaminopropyl)carbodiimide (EDCI) / N-hydroxysuccinimide (HOSu), stir and perform a condensation reaction to obtain Fmoc-Arg(Pbf)-Gly (intermediate 1)
[0084] Add dissolved H-Asp(OtBu)-OH to intermediate 1, and add an appropriate amount of 1-ethyl-(3-dimethylaminopropyl)carbodiimide (EDCI) / N-hydroxysuccinimide (HOSu); stir to carry out condensation reaction to obtain Fmoc-Arg(Pbf)-Gly-Asp(OtBu)-OH.
[0085] 2.2 Using Rink amide MHBA Resin as the starting carrier, the peptide resin was prepared by coupling with the protected amino acids shown in Table 2 in sequence through Fmoc removal and coupling reaction. The protected amino acids corresponding to the protected amino acids used in this example are shown in Table 2 below, where the Fmoc-Arg(Pbf)-Gly-Asp(OtBu)-OH fragment reduces the coupling reaction steps and improves efficiency.
[0086] Table 2 Protected amino acids
[0087]
[0088]
[0089] The preparation is carried out one by one from the C-terminus to the N-terminus according to the amino acid sequence (from large to small). Take Rink amide MHBA Resin resin (substitution value S = 0.37mmol / g). The condensation system adopts HOBT / DIC; the coupling reaction temperature is controlled at 25±5℃, and the coupling reaction time is 1.5-3.5h; 20% PIP / DMF solution is used for deprotection, and the Fmoc-free resin is obtained by filtration.
[0090] 2.3 Comparison of the effects of using Fmoc-Gly-Gly-OH and Fmoc-Arg(Pbf)-Gly-Asp(OtBu)-OH on the synthesis of 30 peptides
[0091] The preparation is carried out one by one from the C-terminus to the N-terminus according to the amino acid sequence (from large to small). Take Rink amide MHBA Resin resin. The condensation system adopts HOBT / DIC; the coupling reaction temperature is controlled at 25±5℃, and the coupling reaction time is 1.5-3.5h; use 20% PIP / DMF solution for deprotection, and filter to obtain the resin without Fmoc.
[0092] 2.4 Preparation of crude polypeptide, the preparation method is the same as that of 1.3 of Example 1. The crude polypeptide has a purity of 69.74%. Figure 2 shown.
[0093] Table 3 Comparison of purity and yield of different fragments
[0094] Snippet Crude purity Amino acid coupling ( Figure 3 ) 52.55% Fmoc-Gly-Gly-OH 62.93% Fmoc-Arg(Pbf)-Gly-Asp(OtBu)-OH 69.74%
[0095] The results in the table above show that the target peptide was synthesized by the fragment method, and the crude product purity was significantly improved. The peptide synthesized by the Fmoc-Arg(Pbf)-Gly-Asp(OtBu)-OH fragment reduced one step of synthesis and significantly improved the crude product purity compared to the peptide synthesized by the Fmoc-Gly-Gly-OH fragment.
[0096] Example 3. Solid phase synthesis of a 30-mer peptide containing GG and RGDRGD fragments using Fmoc-Gly-Gly-OH and Fmoc-Arg(Pbf)-Gly-Asp(OtBu)-OH
[0097] Using Rink amide MHBA Resin as the starting carrier, the peptide resin was prepared by de-Fmoc protection and coupling reaction, and then coupled with the protected amino acids shown in Table 4 in sequence. The protected amino acids corresponding to the protected amino acids used in this example are shown in Table 4 below, where Fmoc-Gly-Gly-OH and Fmoc-Arg(Pbf)-Gly-Asp(OtBu)-OH fragments reduce the coupling reaction steps and improve efficiency.
[0098] Table 4 Protected amino acids
[0099]
[0100]
[0101] The preparation is carried out one by one from the C-terminus to the N-terminus according to the amino acid sequence (from large to small). Take Rink amide MHBA Resin resin (substitution value S = 0.37mmol / g). The condensation system adopts HOBT / DIC; the coupling reaction temperature is controlled at 25±5℃, and the coupling reaction time is 1.5-3.5h; 20% PIP / DMF solution is used for deprotection, and the Fmoc-free resin is obtained by filtration.
[0102] The preparation method of the crude polypeptide is the same as that of the preparation of the crude polypeptide in 1.3 of Example 1. The crude polypeptide has a purity of 74.07%. Figure 4 shown.
[0103] Table 5 Comparison of purity and yield of different fragments
[0104] Snippet Crude purity Amino acid coupling ( Figure 3 ) 52.55% Fmoc-Gly-Gly-OH 62.93% Fmoc-Arg(Pbf)-Gly-Asp(OtBu)-OH 69.74% Fmoc-Gly-Gly-OH and Fmoc-Arg(Pbf)-Gly-Asp(OtBu)-OH 74.07%
[0105] The results in Table 5 above show that the use of two amino acid fragments to synthesize the RGD peptide reduces the number of synthesis steps, saves costs, and the crude product has the highest purity, i.e., 74.07%.
Claims
1. A method for synthesizing an RGD peptide, characterized in that: The synthesis method comprises the following steps: using a solid phase material as a carrier, sequentially coupling amino acid residues modified with side chain protective groups in a condensation system, and finally coupling Fmoc-Arg(Pbf)-Gly-Asp(OtBu)-OH, and then cleaving and removing the side chain protective groups to obtain the RGD peptide.
2. The synthesis method according to claim 1, characterized in that The RGD peptide is a 30-mer peptide, and its amino acid sequence is shown in SEQ ID NO:
1.
3. The synthesis method according to claim 2, characterized in that The synthetic method couples the RGD fragment twice in succession.
4. The synthesis method according to claim 1, characterized in that First, Fmoc-Gly-Gly-OH is connected to the solid phase material, and then the amino acid residues modified with the side chain protecting groups are coupled in sequence, and then Fmoc-Arg(Pbf)-Gly-Asp(OtBu)-OH is coupled twice, and the side chain protecting groups are removed by cleavage to obtain the RGD peptide.
5. The synthesis method according to claim 1, characterized in that The coupling reaction of the coupling is performed from the C-terminus to the N-terminus, and / or the solid phase material is a resin.
6. The synthesis method according to claim 5, characterized in that The solid phase material is Rink amide AM Resin or Rink amide MHBA Resin.
7. The synthesis method according to claim 1, characterized in that The amino acid modified by the side chain protecting group is Fmoc-X-OH, wherein X is an amino acid residue.
8. The synthesis method according to claim 7, characterized in that The side chains of the amino acid residues are also modified with one or more of the following protecting groups: tBu, Trt, OtBu and Pbf.
9. The synthesis method according to claim 8, characterized in that The Fmoc-X-OH is Fmoc-Met-OH, Fmoc-Ser(tBu)-OH, Fmoc-Leu-OH, Fmoc-Pro-OH, Fmoc-Asn(Trt)-OH, Fmoc-Ala-OH , Fmoc-Val-OH, Fmoc-His(Trt)-OH, Fmoc-Gln(Trt)-OH, Fmoc-Phe-OH, Fmoc-Asp(OtBu)-OH or Fmoc-Arg(Pbf)-OH.
10. The synthesis method according to claim 1, characterized in that The condensation system is HOBT / DIC, which is firstly deprotected by Fmoc before the coupling.
11. The synthesis method according to claim 10, characterized in that The de-Fmoc protection uses a PIP / DMF solution; The cleavage reagent used in the cleavage is a mixture of TFA / Mpr / H2O / DMS.
12. The synthesis method according to claim 11, characterized in that The de-Fmoc protection uses a 20% PIP / DMF solution; In the lysis reagent, the volume ratio of TFA / Mpr / H2O / DMS is 92:2:2:2; After cleavage, the RGD peptide is obtained by filtration, concentration and precipitation.
13. The synthesis method according to claim 12, characterized in that: The synthesis method comprises adding isopropyl ether for precipitation.
14. The synthesis method according to claim 1, characterized in that The condensation reagent used in the coupling reaction is one or more of EDCI / HOSu, CDI / base, DCC / HOSu, PivCl and SOCl2 / DCM, the temperature of the coupling reaction is 10-40°C, and / or the time of the coupling reaction is 1-3.5 hours.
15. The synthesis method according to any one of claims 1 to 14, characterized in that: The coupling reaction temperature is one of 15±2°C, 25±2°C and 35±2°C; the coupling reaction time is one of 1h, 2h and 3h.
16. The synthesis method according to claim 4, characterized in that: The coupling reaction comprises coupling the following protected amino acids sequentially from the C-terminus to the N-terminus: Fmoc-Met-OH; Fmoc-Gly-Gly-OH or Fmoc-Gly-OH, Fmoc-Gly-OH; Fmoc-Ser(tBu)-OH, Fmoc-Leu-OH, Fmoc-Pro-OH, Fmoc-Ser(tBu)-OH, Fmoc-Asn(Trt)-OH, Fmoc-Leu-OH, Fmoc-Ala-OH, Fmoc-Val-OH, Fmoc-Leu-OH, Fmoc-His(Trt)-OH, Fmoc-Leu-OH, Fmoc-Val-OH, Fmoc-Pro-OH, Fmoc-Gln(Trt)-OH, Fmoc-Phe-OH, Fmoc-Asp(OtBu)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-His(Trt )-OH, Fmoc-Ser(tBu)-OH, Fmoc-His(Trt)-OH, Fmoc-Met-OH, Fmoc-Arg(Pbf)-Gly-Asp(OtBu)-OH, Fmoc-Arg(Pbf)-Gly-Asp(OtBu)-OH.
17. Application of Fmoc-Arg(Pbf)-Gly-Asp(OtBu)-OH in the preparation of polypeptide drugs; The polypeptide is a 30-mer peptide, and its amino acid sequence is shown in SEQ ID NO:1.
Citation Information
Patent Citations
Highly effective polypeptide for inhibiting angiogenesis, physical chemistry modifying method and application thereof
CN101143894A
Cell adhesion promoting polypeptide and preparation method thereof
CN101817873A
Anti-tumor polypeptide, preparation method and anti-tumor applications thereof
CN102924578A
Antitumor polypeptide, and preparation method and application thereof
CN104530199A
Bivalirudin solid-phase synthesis method
CN104530224A
